Telix Pharmaceuticals is trading at $9.15, down 4.09%, as its Q3 sequential slowdown disappoints investors.
- Q3 revenue rose 19% year over year to US$245 million but fell 1% from Q2.
- Management said FY26 revenue is tracking toward the upper end of guidance; total revenue and other income are expected to exceed US$1 billion.
- Healthcare weakness may add pressure. No fresh October 23 company announcement was identified; supplied price context shows consecutive daily declines, and current-session volume is unavailable.